Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Able Labs

Executive Summary

Dingell subcommittee's interest in the generic firm is focused on the company's conjugated estrogens ANDA and the events surrounding FDA's policy change on bioequivalence requirements for generic versions of Wyeth-Ayerst's Premarin, Able says. Attachments to a March 14 letter from Rep. Dingell (D-Mich.) and Rep. Bliley (R-Va.) to HHS Secretary Sullivan on the investigation of FDA's generic division list Able as one of six companies for which Dingell is seeking compliance records and AF jackets from FDA ("The Pink Sheet" March 27, p. 7). Able says it is not involved in the ongoing criminal investigation by a Baltimore grand jury.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel